Literature DB >> 2910211

Chronic TNF infusion causes anorexia but not accelerated nitrogen loss.

H R Michie1, M L Sherman, D R Spriggs, J Rounds, M Christie, D W Wilmore.   

Abstract

It has been proposed that many of the physiologic and metabolic changes that occur during critical illness and malignancy are mediated by the cytokine tumor necrosis factor alpha/cachectin (TNF). To test this hypothesis, a study of the metabolic responses that occurred during 5 days of continuous intravenous (I.V.) infusion of TNF both in rats and tumor-bearing humans was conducted. TNF administration was associated with anorexia, fluid retention, acute phase responses, and negative nitrogen balance. In both species, changes in nitrogen balance were related to the onset of anorexia and not to the development of hypermetabolism and accelerated net tissue breakdown. TNF may represent the primary afferent stimulus inducing many of the metabolic changes that occur during critical illness, but it is not solely responsible for the accelerated net proteolysis that occurs in these patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910211      PMCID: PMC1493883          DOI: 10.1097/00000658-198901000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

Authors:  M L Sherman; D R Spriggs; K A Arthur; K Imamura; E Frei; D W Kufe
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

Review 2.  Lymphokines.

Authors:  C A Dinarello; J W Mier
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

Review 3.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

4.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

Review 5.  Cachectin and tumour necrosis factor as two sides of the same biological coin.

Authors:  B Beutler; A Cerami
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

6.  The acute metabolic effects of tumor necrosis factor administration in humans.

Authors:  R S Warren; H F Starnes; J L Gabrilove; H F Oettgen; M F Brennan
Journal:  Arch Surg       Date:  1987-12

7.  Chronic arterial and venous access in the unrestrained rat.

Authors:  M E Burt; J Arbeit; M F Brennan
Journal:  Am J Physiol       Date:  1980-04

8.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

9.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.

Authors:  K J Tracey; S F Lowry; T J Fahey; J D Albert; Y Fong; D Hesse; B Beutler; K R Manogue; S Calvano; H Wei
Journal:  Surg Gynecol Obstet       Date:  1987-05

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  15 in total

Review 1.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

2.  Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes.

Authors:  T G Kirchgessner; K T Uysal; S M Wiesbrock; M W Marino; G S Hotamisligil
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

Authors:  G Strassmann; M Fong; J S Kenney; C O Jacob
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Lipopolysaccharide (LPS) increases the in vivo oxidation of branched-chain amino acids in the rat: a cytokine-mediated effect.

Authors:  C García-Martínez; M Llovera; F J López-Soriano; B del Santo; J M Argilés
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

5.  Regulation of bitter taste responses by tumor necrosis factor.

Authors:  Pu Feng; Masafumi Jyotaki; Agnes Kim; Jinghua Chai; Nirvine Simon; Minliang Zhou; Alexander A Bachmanov; Liquan Huang; Hong Wang
Journal:  Brain Behav Immun       Date:  2015-04-21       Impact factor: 7.217

Review 6.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Authors:  R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Early hormonal changes affect the catabolic response to trauma.

Authors:  P Q Bessey; K A Lowe
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

9.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Authors:  S H Murch; V A Lamkin; M O Savage; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

10.  The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations.

Authors:  Y Noguchi; T Makino; T Yoshikawa; K Nomura; K Fukuzawa; A Matsumoto; T Yamada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.